Special Situation Alert: Time to Buy a Biotech Breakup?

In this segment from Market Checkup, Motley Fool health-care analysts David Williamson and Michael Douglass discuss Baxter International's (NYSE: BAX  )  decision to follow the popular Big Pharma route by splitting.

It appears Baxter is no longer content to spin off underperforming units, but is instead taking a long-hoped-for dramatic reshaping to unlock value for shareholders. This special situation could offer investors two dramatically different investing opportunities.

The closest analogy here is Abbott Labs (NYSE: ABT  ) and AbbVie (NYSE: ABBV  ) , for a number of reasons. Both suffered from a short-term overhang but have potential for outperformance. In AbbVie's case it is patent expiration for the world's best-selling drug, Humira, while Baxter faces competition from Biogen Idec (NASDAQ: BIIB  ) . However, both pharma units have interesting pipelines, and AbbVie has rewarded investors, as its 45% return since breaking off from its former parent company has doubled that of Abbott Labs.

Watch and find out why David and Micheal agree with Baxter's decision, what each of the new businesses offers for investors, and how much upside there could be for shareholders.

3 stocks poised to be multibaggers
The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have found multibagger stocks time and again. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2896439, ~/Articles/ArticleHandler.aspx, 8/30/2015 8:59:26 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

David Williamson

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Today's Market

updated 1 day ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:00 PM
BAX $38.75 Up +0.16 +0.41%
Baxter Internation… CAPS Rating: *****
ABBV $63.98 Down -0.53 -0.82%
AbbVie Inc. CAPS Rating: ****
ABT $46.02 Up +0.38 +0.83%
Abbott Laboratorie… CAPS Rating: *****
BIIB $303.69 Down -0.80 -0.26%
Biogen Idec CAPS Rating: ****